{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:08:58Z","timestamp":1776208138747,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010573","name":"Dioraphte Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-01251"],"award-info":[{"award-number":["2022-01251"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["MR\/P027989\/1"],"award-info":[{"award-number":["MR\/P027989\/1"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jchromb.2024.124377","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T20:30:05Z","timestamp":1731443405000},"page":"124377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices"],"prefix":"10.1016","volume":"1250","author":[{"given":"Wietse M.","family":"Schouten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrien","family":"Van Bocxlaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadel M.","family":"Kratz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles E.","family":"Mowbray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.C.","family":"Dorlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2024.124377_b0005","unstructured":"World Health Organization (WHO), Global leishmaniasis surveillance, 2022: assessing trends over the past 10 years (2023)."},{"key":"10.1016\/j.jchromb.2024.124377_b0010","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1469-0691.2011.03630.x","article-title":"Leishmaniasis chemotherapy\u2014challenges and opportunities","volume":"17","author":"Croft","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jchromb.2024.124377_b0015","doi-asserted-by":"crossref","unstructured":"C. Mowbray, Chapter 2: Anti-leishmanial Drug Discovery: Past, Present and Future Perspectives, 2018, pp. 24-36.","DOI":"10.1039\/9781788010177-00024"},{"key":"10.1016\/j.jchromb.2024.124377_b0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/13543776.2018.1473379","article-title":"Benzoxaborole compounds for therapeutic uses: a patent review (2010\u20132018)","volume":"28","author":"Nocentini","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jchromb.2024.124377_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.132057","article-title":"Benzoxaboroles: New emerging and versatile scaffold with a plethora of pharmacological activities","volume":"1252","author":"Dhawan","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jchromb.2024.124377_b0030","first-page":"129","article-title":"Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis","volume":"11","author":"Van Bocxlaer","year":"2019","journal-title":"Int. J. Parasitol.: Drugs Drug Resist."},{"key":"10.1016\/j.jchromb.2024.124377_b0035","doi-asserted-by":"crossref","first-page":"16159","DOI":"10.1021\/acs.jmedchem.1c01437","article-title":"DNDI-6148: A novel benzoxaborole preclinical candidate for the treatment of visceral leishmaniasis","volume":"64","author":"Mowbray","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jchromb.2024.124377_b0040","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1016\/j.bmc.2016.11.008","article-title":"Animal models in the pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents","volume":"24","author":"Zhao","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jchromb.2024.124377_b0045","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3390\/antibiotics10121485","article-title":"Predicting antimicrobial activity at the target site: pharmacokinetic\/pharmacodynamic indices versus time-kill approaches","volume":"10","author":"van Os","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jchromb.2024.124377_b0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/cts.12448","article-title":"Importance of drug pharmacokinetics at the site of action","volume":"10","author":"Rizk","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jchromb.2024.124377_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113590","article-title":"Skin tissue sample collection, sample homogenization, and analyte extraction strategies for liquid chromatographic mass spectrometry quantification of pharmaceutical compounds","volume":"191","author":"Roseboom","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2024.124377_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114402","article-title":"Development and validation of an HPLC-MS\/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue","volume":"207","author":"Roseboom","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2024.124377_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123494","article-title":"Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue","volume":"1211","author":"Roseboom","year":"2022","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2024.124377_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123354","article-title":"Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue","volume":"1206","author":"Roseboom","year":"2022","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2024.124377_b0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0091270007312152","article-title":"Clinical microdialysis in skin and soft tissues: an update","volume":"48","author":"Schmidt","year":"2008","journal-title":"J. Clin. Pharmacol."},{"issue":"63","key":"10.1016\/j.jchromb.2024.124377_b0080","first-page":"e00829","article-title":"Pharmacokinetics and pharmacodynamics of the nitroimidazole DNDI-0690 in mouse models of cutaneous leishmaniasis","volume":"63","author":"Wijnant","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2024.124377_b0085","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkm476","article-title":"Tissue concentrations: do we ever learn?","volume":"61","author":"Mouton","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jchromb.2024.124377_b0090","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ijantimicag.2017.10.001","article-title":"Dermal pharmacokinetics of pyrazinamide determined by microdialysis sampling in rats","volume":"51","author":"Voelkner","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jchromb.2024.124377_b0095","unstructured":"European Medicines Agency (EMA), ICH guideline M10 on bioanalytical method validation - Step 5. https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline, 2022 (accessed 06 May 2024)."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224003866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224003866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T13:37:48Z","timestamp":1733405868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023224003866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":19,"alternative-id":["S1570023224003866"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124377","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124377","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"124377"}}